MX2020004338A - Composiciones de peptidos tau fosforilados y sus usos. - Google Patents
Composiciones de peptidos tau fosforilados y sus usos.Info
- Publication number
- MX2020004338A MX2020004338A MX2020004338A MX2020004338A MX2020004338A MX 2020004338 A MX2020004338 A MX 2020004338A MX 2020004338 A MX2020004338 A MX 2020004338A MX 2020004338 A MX2020004338 A MX 2020004338A MX 2020004338 A MX2020004338 A MX 2020004338A
- Authority
- MX
- Mexico
- Prior art keywords
- tau peptides
- phosphorylated tau
- compositions
- peptides
- conjugates
- Prior art date
Links
- 101000854943 Enterobacteria phage T4 Valyl-tRNA ligase modifier Proteins 0.000 title abstract 5
- 239000000203 mixture Substances 0.000 title 1
- 239000002502 liposome Substances 0.000 abstract 2
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6018—Lipids, e.g. in lipopeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
- A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dispersion Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Marine Sciences & Fisheries (AREA)
- Psychology (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Se describen liposomas que contienen peptidos tau, preferiblemente peptidos tau fosforilados, y conjugados que contienen peptidos tau, preferiblemente peptidos tau fosforilados, conjugados a un vehiculo inmunogenico; tambien se describen composiciones farmaceuticas y usos de los liposomas y/o conjugados para tratar o prevenir una enfermedad o trastorno neurodegenerativo, tal como la enfermedad de Alzheimer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762577157P | 2017-10-25 | 2017-10-25 | |
PCT/US2018/057286 WO2019084118A2 (en) | 2017-10-25 | 2018-10-24 | PHOSPHORYLATED TUBE PEPTIDE COMPOSITIONS AND USES THEREOF |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020004338A true MX2020004338A (es) | 2020-10-14 |
Family
ID=64362628
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020004338A MX2020004338A (es) | 2017-10-25 | 2018-10-24 | Composiciones de peptidos tau fosforilados y sus usos. |
Country Status (22)
Country | Link |
---|---|
US (3) | US11124552B2 (es) |
EP (1) | EP3700556A2 (es) |
JP (2) | JP2021501147A (es) |
KR (1) | KR20200077543A (es) |
CN (2) | CN111787942B (es) |
AR (1) | AR113792A1 (es) |
AU (1) | AU2018355325A1 (es) |
BR (1) | BR112020008168A2 (es) |
CA (1) | CA3079423A1 (es) |
CL (2) | CL2020001070A1 (es) |
CO (1) | CO2020006073A2 (es) |
DO (1) | DOP2020000135A (es) |
EA (1) | EA202091012A1 (es) |
EC (1) | ECSP20026986A (es) |
IL (2) | IL302108A (es) |
JO (1) | JOP20200103A1 (es) |
MA (1) | MA50465A (es) |
MX (1) | MX2020004338A (es) |
PH (1) | PH12020550432A1 (es) |
SG (1) | SG11202003556UA (es) |
TW (2) | TWI827557B (es) |
WO (1) | WO2019084118A2 (es) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR113792A1 (es) | 2017-10-25 | 2020-06-10 | Janssen Pharmaceuticals Inc | Composiciones de péptidos tau fosforilados y sus usos |
SG11202108312PA (en) | 2019-02-08 | 2021-08-30 | Ac Immune Sa | Method of safe administration of phosphorylated tau peptide vaccine |
MX2021012994A (es) * | 2019-04-24 | 2022-03-04 | Janssen Pharmaceuticals Inc | Administracion heterologa de vacunas tau. |
US20220339183A1 (en) * | 2019-09-23 | 2022-10-27 | Macquarie University | Treatment of tauopathies |
CA3161668A1 (en) | 2019-12-20 | 2021-06-24 | Nammi Therapeutics, Inc. | Formulated and/or co-formulated liposome compositions containing toll-like receptor ("tlr") agonist prodrugs useful in the treatment of cancer and methods thereof |
US20230131808A1 (en) * | 2020-04-22 | 2023-04-27 | Southlake Pharmaceuticals, Inc. | Pegylated interferon tau and compositions and methods thereof |
WO2022054795A1 (ja) * | 2020-09-08 | 2022-03-17 | 国立大学法人大阪大学 | リン酸化タウタンパク質を標的とする免疫原性組成物 |
AU2022328342A1 (en) * | 2021-08-12 | 2024-02-22 | Ac Immune Sa | Liposomes containing phosphorylated tau peptides for inducing sustained immune responses |
WO2023152260A1 (en) * | 2022-02-09 | 2023-08-17 | Ac Immune Sa | Anti-alpha-synuclein therapeutic vaccines |
WO2024015611A2 (en) * | 2022-07-14 | 2024-01-18 | Vaxxinity, Inc. | Tau peptide immunogen constructs |
Family Cites Families (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5811310A (en) | 1986-09-30 | 1998-09-22 | Albert Einstein College Of Medicine Of Yeshiva Univ. | The Alz-50 monoclonal antibody and diagnostic assay for alzheimer's disease |
JPH0832638B2 (ja) | 1989-05-25 | 1996-03-29 | カイロン コーポレイション | サブミクロン油滴乳剤を含んで成るアジュバント製剤 |
US7408027B1 (en) | 1991-12-06 | 2008-08-05 | Max-Planck-Gesellschaft Zur Forderung Der Wissenchaften | Tools for the diagnosis and treatment of Alzheimer's disease |
AU690092B2 (en) | 1992-12-14 | 1998-04-23 | N.V. Innogenetics S.A. | Monoclonal antibodies directed against the microtubule-associated protein tau, hybridomas secreting these antibodies, antigen recognition by these monoclonal antibodies and their applications |
US7427392B1 (en) | 1994-11-14 | 2008-09-23 | Elan Pharmaceuticals, Inc. | Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau |
US20020086009A1 (en) | 1996-03-13 | 2002-07-04 | Koichi Ishiguro | Anti-phosphorylated tau protein antibodies and methods for detecting alzheimer`s disease with the use of the same |
WO1998022120A1 (en) | 1996-11-19 | 1998-05-28 | The Wistar Institute Of Anatomy & Biology | Diagnostic and therapeutic reagents for alzheimer's disease |
EA003739B1 (ru) | 1997-12-03 | 2003-08-28 | Байоджен, Инк. | Гидрофобно-модифицированные белки, способы их получения и их применение |
US6314469B1 (en) | 1999-02-26 | 2001-11-06 | I-Dns.Net International Pte Ltd | Multi-language domain name service |
EP1301531A2 (en) | 2000-07-11 | 2003-04-16 | Molecular Geriatrics Corporation | Reagents and methods for identification of binding agents |
GB0114719D0 (en) | 2001-06-15 | 2001-08-08 | Glaxo Group Ltd | Compound |
JP2005526497A (ja) | 2002-02-04 | 2005-09-08 | ビオミラ,インコーポレーテッド | 免疫刺激性、共有結合性脂質化オリゴヌクレオチド |
PL209696B1 (pl) | 2002-04-19 | 2011-10-31 | Univ Toronto | Peptyd, kompozycja peptydowa, kompozycja immunogenna, zastosowania kompozycji immunogennej oraz sposób określania czy związek stanowi inhbitor odkładania się i tworzenia włókienek amyloidu |
WO2004058239A1 (en) | 2002-12-24 | 2004-07-15 | Neurochem (International) Limited | Therapeutic formulations for the treatment of beta-amyloid related diseases |
US8663650B2 (en) | 2003-02-21 | 2014-03-04 | Ac Immune Sa | Methods and compositions comprising supramolecular constructs |
US7901348B2 (en) | 2003-12-12 | 2011-03-08 | University Of Washington | Catheterscope 3D guidance and interface system |
US20050261475A1 (en) | 2004-02-13 | 2005-11-24 | Harvard Medical School | Solid-phase capture-release-tag methods for phosphoproteomic analyses |
US7238788B2 (en) | 2004-02-18 | 2007-07-03 | University Of Iowa Foundation | Antibodies to phosphorylated tau, methods of making and methods of use |
EP1879613B1 (en) | 2005-05-05 | 2011-11-30 | Merck Sharp & Dohme Corp. | Peptide conjugate compositions and methods for the prevention and treatment of alzheimer's disease |
AU2006326283B2 (en) | 2005-12-12 | 2012-01-19 | Ac Immune S.A. | Therapeutic vaccine |
WO2007068105A1 (en) | 2005-12-12 | 2007-06-21 | Robarts Research Institute | Method of diagnosing amyotrophic lateral sclerosis |
JP5823663B2 (ja) | 2006-03-03 | 2015-11-25 | プロミス ニューロサイエンシズ インコーポレイテッド | ミスフォールドsod1媒介疾患を処置および検出するための方法および組成物 |
US8012936B2 (en) | 2006-03-29 | 2011-09-06 | New York University | Tau fragments for immunotherapy |
WO2008140639A2 (en) | 2007-02-08 | 2008-11-20 | Oligomerix, Inc. | Biomarkers and assays for alzheimer's disease |
KR20100115340A (ko) | 2007-10-19 | 2010-10-27 | 이무나스 파마 가부시키가이샤 | Aβ 올리고머에 특이적으로 결합하는 항체 및 그의 이용 |
US9498522B2 (en) | 2008-08-07 | 2016-11-22 | Mercia Pharma Inc. | Immunotherapeutic compositions for the treatment of alzheimer'S disease |
US20100233095A1 (en) | 2009-01-30 | 2010-09-16 | Adlyfe, Inc. | Conformationally dynamic peptides |
US9605054B2 (en) | 2009-02-23 | 2017-03-28 | The Board Of Trustees Of The University Of Illinois | Composition and method for treating a tauopathy |
WO2010106127A2 (en) | 2009-03-18 | 2010-09-23 | Ac Immune S.A. | Method for therapeutic use |
UA107571C2 (xx) | 2009-04-03 | 2015-01-26 | Фармацевтична композиція | |
CA2765099A1 (en) | 2009-06-10 | 2010-12-16 | New York University | Phosphorylated tau peptide for use in the treatment of tauopathy |
JP2013500326A (ja) * | 2009-07-30 | 2013-01-07 | ファイザー バクシーンズ エルエルシー | 抗原性タウペプチドおよびその使用 |
US20130022982A1 (en) | 2009-09-14 | 2013-01-24 | Kevin Ka-Wang Wang | Micro-rna, autoantibody and protein markers for diagnosis of neuronal injury |
EP3231446A1 (en) | 2010-04-19 | 2017-10-18 | Nlife Therapeutics S.L. | Compositions and methods for selective delivery of oligonucleotide molecules to specific neuron types |
WO2012020124A1 (en) | 2010-08-12 | 2012-02-16 | Ac Immune S.A. | Vaccine engineering |
KR101854943B1 (ko) | 2010-10-26 | 2018-05-04 | 에이씨 이뮨 에스.에이. | 소수성 부분을 통해 변형된 펩티드를 포함하는 리포솜 기반 구조체 |
GB201112056D0 (en) * | 2011-07-14 | 2011-08-31 | Univ Leuven Kath | Antibodies |
CN109265543B (zh) | 2011-09-19 | 2022-04-26 | 阿克松神经***科学公司 | 阿尔茨海默病中的tau蛋白介导病变的基于蛋白质的疗法和诊断 |
US20140314837A1 (en) | 2011-09-23 | 2014-10-23 | Ac Immune S. A. | Vaccine Therapy |
WO2013058350A1 (ja) | 2011-10-21 | 2013-04-25 | 三菱化学株式会社 | 周期表第13族金属窒化物半導体結晶の製造方法、及び該製造方法により製造される周期表第13族金属窒化物半導体結晶 |
EP2659906A1 (en) | 2012-05-01 | 2013-11-06 | Affiris AG | Compositions |
US20170368167A9 (en) * | 2012-08-21 | 2017-12-28 | The Institute For Molecular Medicine | Compositions and methods related to neurological disorders |
US20140056901A1 (en) | 2012-08-21 | 2014-02-27 | The Institute For Molecular Medicine | Anti-tau antibodies and compositions for and methods of making and using in treatment, diagnosis and monitoring of tauopathies |
EP3689904A1 (en) | 2013-03-13 | 2020-08-05 | Prothena Biosciences Limited | Tau immunotherapy |
WO2015122922A1 (en) | 2014-02-14 | 2015-08-20 | Ipierian, Inc. | Tau peptides, anti-tau antibodies, and methods of use thereof |
CN107074965B (zh) | 2014-06-26 | 2021-08-03 | 扬森疫苗与预防公司 | 特异性结合微管相关蛋白tau的抗体和抗原结合片段 |
MA44955A (fr) | 2015-06-05 | 2019-03-20 | Ac Immune Sa | Anticorps anti-tau et leurs méthodes d'utilisation |
BR112017028269A2 (pt) | 2015-07-13 | 2018-09-04 | Arvinas Inc | composto, composição farmacêutica, uso de uma quantidade efetiva de um composto, estado ou condição de doença, e, método para identificar um composto. |
WO2017030913A2 (en) | 2015-08-14 | 2017-02-23 | Intuitive Surgical Operations, Inc. | Systems and methods of registration for image-guided surgery |
AU2017259038B2 (en) | 2016-05-02 | 2024-05-23 | Prothena Biosciences Limited | Antibodies recognizing Tau |
AU2017373889A1 (en) | 2016-12-07 | 2019-06-06 | Ac Immune Sa | Anti-Tau antibodies and methods of use |
AR113792A1 (es) * | 2017-10-25 | 2020-06-10 | Janssen Pharmaceuticals Inc | Composiciones de péptidos tau fosforilados y sus usos |
EP3706795A4 (en) | 2017-11-09 | 2021-10-13 | Pinteon Therapeutics Inc. | METHODS AND COMPOSITIONS FOR GENERATING AND USING HUMANIZED CONFORMATION SPECIFIC PHOSPHORYLATED TAU ANTIBODIES |
SG11202108312PA (en) * | 2019-02-08 | 2021-08-30 | Ac Immune Sa | Method of safe administration of phosphorylated tau peptide vaccine |
MX2021012994A (es) | 2019-04-24 | 2022-03-04 | Janssen Pharmaceuticals Inc | Administracion heterologa de vacunas tau. |
-
2018
- 2018-10-24 AR ARP180103100A patent/AR113792A1/es unknown
- 2018-10-24 JO JOP/2020/0103A patent/JOP20200103A1/ar unknown
- 2018-10-24 CA CA3079423A patent/CA3079423A1/en active Pending
- 2018-10-24 CN CN201880083892.2A patent/CN111787942B/zh active Active
- 2018-10-24 KR KR1020207014520A patent/KR20200077543A/ko active IP Right Grant
- 2018-10-24 TW TW107137586A patent/TWI827557B/zh active
- 2018-10-24 SG SG11202003556UA patent/SG11202003556UA/en unknown
- 2018-10-24 AU AU2018355325A patent/AU2018355325A1/en active Pending
- 2018-10-24 JP JP2020523284A patent/JP2021501147A/ja active Pending
- 2018-10-24 TW TW112117496A patent/TW202333768A/zh unknown
- 2018-10-24 MA MA050465A patent/MA50465A/fr unknown
- 2018-10-24 IL IL302108A patent/IL302108A/en unknown
- 2018-10-24 BR BR112020008168-0A patent/BR112020008168A2/pt unknown
- 2018-10-24 EP EP18804745.0A patent/EP3700556A2/en active Pending
- 2018-10-24 US US16/169,215 patent/US11124552B2/en active Active
- 2018-10-24 EA EA202091012A patent/EA202091012A1/ru unknown
- 2018-10-24 WO PCT/US2018/057286 patent/WO2019084118A2/en unknown
- 2018-10-24 US US16/757,621 patent/US11958889B2/en active Active
- 2018-10-24 CN CN202310829637.0A patent/CN117298259A/zh active Pending
- 2018-10-24 MX MX2020004338A patent/MX2020004338A/es unknown
-
2020
- 2020-04-15 PH PH12020550432A patent/PH12020550432A1/en unknown
- 2020-04-16 IL IL273980A patent/IL273980A/en unknown
- 2020-04-21 CL CL2020001070A patent/CL2020001070A1/es unknown
- 2020-05-18 CO CONC2020/0006073A patent/CO2020006073A2/es unknown
- 2020-05-22 EC ECSENADI202026986A patent/ECSP20026986A/es unknown
- 2020-07-02 DO DO2020000135A patent/DOP2020000135A/es unknown
-
2021
- 2021-01-27 CL CL2021000217A patent/CL2021000217A1/es unknown
- 2021-08-19 US US17/445,419 patent/US20210388044A1/en active Pending
-
2023
- 2023-02-09 JP JP2023018374A patent/JP2023071688A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2020004338A (es) | Composiciones de peptidos tau fosforilados y sus usos. | |
CL2020002024A1 (es) | Moduladores de calpaínas y usos terapeuticos de los mismos. (divisional solicitud 201900793) | |
CL2020000501A1 (es) | Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp1) y usos de los mismos. | |
BR112019000528A2 (pt) | distribuição mediada por ve de conjugados de proteína de ligação-molécula pequena | |
CL2019002240A1 (es) | Dendrímeros terapéuticos. | |
AR093705A1 (es) | Depsipeptido y sus usos | |
CL2019000115A1 (es) | Compuestos y métodos para la modulación de smn2. | |
CO2019012767A2 (es) | Compuesto de fenil-2-hidroxi-acetilamino-2-metil-fenilo | |
CL2017002334A1 (es) | Combinaciones y formulaciones de dosis fijas que comprenden etc-1002 y una o más estatinas y métodos para tratar o reducir el riesgo de enfermedad cardiovascular | |
CL2017002299A1 (es) | Combinaciones de dosis fija y formulaciones comprendiendo etc-1002 y ezetimiba y métodos para tratar o reducir el riesgo de enfermedades cardiovasculares | |
CY1122441T1 (el) | Καινοτομες ενωσεις και συζευγματα κρυπτοφυκινης, η παρασκευη τους και η θεραπευτικη χρηση τους | |
ECSP17069696A (es) | Compuestos novedosos | |
ECSP16084317A (es) | Formulaciones farmacéuticas, procesos para la preparación y métodos de uso | |
CU20210077A7 (es) | Extractos bacterianos estables como fármacos | |
MX2018000239A (es) | Bifosfonatos de hbed, sus conjugados radio metalicos y su uso como agentes teranosticos. | |
EA201991196A1 (ru) | Претерпевшие самосборку диблок-сополимеры, состоящие из pegmema и несущих лекарственное средство полимерных сегментов | |
CO2018013828A2 (es) | Composiciones farmacéuticas de oligómero de morfolino fósforodiamidato | |
MX2019001634A (es) | Compuestos amidas, composiciones farmacéuticas de estos y métodos para utilizarlos. | |
PE20151603A1 (es) | Anticuerpos anti-lamp1 y conjugados anticuerpo farmaco, y usos de estos | |
BR112022000297A2 (pt) | Conjugados de peptídeos de agentes de alvo de microtúbulos como terapêuticos | |
BR112018016715A2 (pt) | ?formulações de oritavancina? | |
CO2021008962A2 (es) | Derivados activos de éster de testosterona, composiciones y usos de los mismos | |
CL2017003500A1 (es) | Síntesis total de shishijimicina a y sus análogos | |
WO2018094035A3 (en) | Ligand ionophore conjugates | |
EA201891848A1 (ru) | Фармацевтическая композиция для применения в лечении фиброза |